Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 5:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 99 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) Clear all

Conditions: Schizophrenia, Fatty Acid Deficiency
Interventions: Omega-3 Fatty Acids, Olive oil placebo, EPA fish oil concentrate; DHA fish oil concentrate, Placebo; Dietary Supplement · Other · Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 8 Years to 25 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Epilepsy
Interventions: Placebo, High Dose Fish Oil, Low Dose Fish Oil; Drug
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Health Effects of Ambient Air Pollution
Interventions: omega-3 fatty acids; Dietary Supplement
Lead sponsor: U.S. EPA Human Studies Facility; Federal
Eligibility: 25 Years to 55 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Posttraumatic Stress Disorder
Interventions: Omega-3 Fatty Acid, Placebo; Drug
Lead sponsor: Durham VA Medical Center; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hypertriglyceridemia
Interventions: warfarin, omefas, omega-3-acid ethyl esters; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Diabetes
Interventions: Vitamin D, Omega-3 fatty acids (fish oil), Vitamin D placebo, Fish oil placebo; Dietary Supplement · Drug
Lead sponsor: University of Washington; Other
Eligibility: 50 Years and older
Enrollment: 1,312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Keratoconjunctivitis Sicca
Interventions: Omega-3 Fatty Acid, Soybean Soft Gels; Dietary Supplement
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Hot Flashes, Menopause, Vasomotor Symptoms
Interventions: Placebo, Omega-3, Yoga, Exercise, Usual Activity; Dietary Supplement · Behavioral
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 40 Years to 62 Years · Female only
Enrollment: 355 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 3
States / cities: Oakland, California • Indianapolis, Indiana • Seattle, Washington

Conditions: Cardiovascular Disease, HIV Infection
Interventions: Lovaza, Placebo; Drug
Lead sponsor: Tufts University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertriglyceridemia
Interventions: AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo; Drug
Lead sponsor: Amarin Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 702 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 80
States / cities: Muscle Shoals, Alabama • Scottsboro, Alabama • Phoenix, Arizona + 69 more

Conditions: Non-Alcoholic Fatty Liver Disease
Interventions: Fish Oil Supplementation, Placebo Supplementation; Drug
Lead sponsor: Columbia University; Other
Eligibility: 12 Years to 18 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Bone Density, Body Composition, Bone Health
Interventions: Vitamin D3 placebo, Fish oil placebo, omega-3 fatty acids (fish oil), Vitamin D3; Dietary Supplement
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 50 Years and older
Enrollment: 771 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Age-related Macular Degeneration, Cataract
Interventions: Lutein/zeaxanthin, DHA/EPA, Lutein/zeaxanthin and DHA/EPA; Dietary Supplement · Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 50 Years to 85 Years
Enrollment: 4,203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 91
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 72 more

Conditions: Dry Eye Syndrome
Interventions: Omega-3 fatty acid supplement, Placebo; Dietary Supplement
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hypertriglyceridemia
Interventions: 4/day of 4g P-OM3 capsules, 4/day of 1g P-OM3 capsules, Corn Oil Placebo, 4 capsules/day for 8 weeks; Drug
Lead sponsor: Penn State University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Infections, Human Cathelicidin Antimicrobial Peptide (hCAP-18)
Interventions: vitamin D3, omega-3 fatty acids (fish oil), Vitamin D3 placebo, fish oil placebo; Dietary Supplement · Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 50 Years and older
Enrollment: 25,874 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertriglyceridemia
Interventions: DHA-rich fish oil versus Phospholipid-rich fish oil; Dietary Supplement
Lead sponsor: Arctic Nutrition AS; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: Healthy, Dietary Supplement
Interventions: Ozone, Fish Oil, Olive Oil; Drug · Dietary Supplement
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 35 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Brain Trauma
Interventions: Plasma Neurofilament Light (NF-L), Omega-3 Index, HeadCount Questionnaire; Other
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 25 Years · Female only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Kansas City, Missouri

Conditions: Hypertension
Interventions: Vitamin D-3 (cholecalciferol), 2000 IU, Omega-3 fatty acids (fish oil), Vitamin D placebo, Fish oil placebo; Dietary Supplement · Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 50 Years to 99 Years
Enrollment: 25,875 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Severe Hypertriglyceridemia
Interventions: Epanova (4 g) and Lovaza (4 g), Lovaza (4 g) and Epanova (4 g); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetic Peripheral Neuropathy
Interventions: Blackmores Omega Daily (4 1g capsules per day); Dietary Supplement
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 50 Years to 75 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: BodyBio Balance Oil, Kirunal Fish Oil, BodyBio PC, Modified Paleolithic Elimination diet, Time Restricted Olive Oil Based (TROO) Ketogenic Diet, Usual diet with Dietary Guidelines for Americans Diet information; Dietary Supplement · Behavioral
Lead sponsor: Terry L. Wahls; Other
Eligibility: 18 Years to 70 Years
Enrollment: 162 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Lipid Metabolism Disorders, Hypertriglyceridemia
Interventions: EPA, DHA; Drug
Lead sponsor: The Miriam Hospital; Other
Eligibility: 18 Years to 69 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Providence, Rhode Island

Search by objective public record fields.

Omega-3 Fatty Acid Deficiency Replacement in Early Schizophrenia

Double Blind, Crossover Study of Fish Oil [EPA and DHA] for Intractable Partial Seizures

Effects of Omega-3 Fatty Acids in Ambient Air Pollution Exposure in Healthy Adults

Omega-3 Fatty Acids and Post Traumatic Stress Disorder (PTSD)

Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals

Vitamin D and Omega-3 Trial to Prevent and Treat Diabetic Kidney Disease

Omega-3 Fatty Acid Supplements and Dry Eye

MsFLASH-02: Interventions for Relief of Menopausal Symptoms: A 3-by-2 Factorial Design Examining Yoga, Exercise, and Omega-3 Supplementation

Human Immunodeficiency Virus (HIV), Arterial Dysfunction, Lipids, Lovaza (HALO) Trial

Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study

VITamin D and OmegA-3 TriaL: Effects on Bone Structure and Architecture (VITAL)

Age-Related Eye Disease Study 2 (AREDS2)

A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome

Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides

Effects of Vitamin D and Omega-3 Fatty Acids on Infectious Diseases and hCAP18 (VITAL Infection)

Bioavailability of EPA and DHA From Two Dietary Supplements

Efficacy of Fish Oil or Olive Oil Supplementation on the Health Effects of Ozone Exposure in Healthy Young Subjects

Plasma Neurofilament Light and Its Relationship With Omega-3 Status and Soccer Heading in Women Soccer Players

Vitamin D and Omega-3 Hypertension Trial (VITAL Hypertension)

Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation

Corneal Nerves Function and Structure

Efficacy of Diet on Quality of Life in Multiple Sclerosis

Differential Thrombogenesis by EPA and DHA Mediated by HDL